Author

N. W. van de Donk

Observed name: NWCJV Donk

Institutions: Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam

Observed institutions: Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam

OpenAlex ID: A5111058693

Long-term Follow-up From the Phase 1/2 Majestec-1 Trial of Teclistamab in Patients With Relapsed/refractory Multiple Myeloma: Subgroup Analysis by Lines of Therapies

2024 · LJ Costa, NWCJV Donk, et al. · Hematology Transfusion and Cell Therapy · 4

Teclistamab in Relapsed or Refractory Multiple Myeloma (rrmm): Majestec-1 Subgroup Analysis by Lines of Therapies

2023 · NWCJV Donk, R Popat, et al. · Hematology Transfusion and Cell Therapy · 4

Works count: 2

Citation count: 8

H-index: 2

I10-index: